Limited miR-17-92 overexpression drives hematologic malignancies. Issue 3 (March 2015) - Danielson, Laura S.
Highlights Developed model with limited miR-17-92 overexpression across hematopoietic lineages. miR-17-92 expression is sufficient to drive B cell malignancies. SM22α-cre mediated recombination occurs in virtually all hematopoietic lineages.